Prednisone
Treatment for Inflammatory bowel disease
Typical Dosage: 40-60 mg daily with taper
Effectiveness
88%
Safety Score
50%
Clinical Trials
26
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
40-60 mg daily with taper
Time to Effect
days to 1-2 weeks
Treatment Duration
8-12 weeks with taper
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2.5(Treat 2.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$400
Side Effect Mgmt:$250
Total Annual:$725
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$967
Cost per Remission
$1,611
Comparison vs Placebo
Cost Difference
+$725/year
More expensive
QALY Difference
+0.08 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Prednisone Outcomes
for Inflammatory bowel disease
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Remission Rate
+45%
Common Side Effects
Insomnia, mood changes
+40%
Fluid retention, weight gain
+30%
Hyperglycemia
+15%
Osteoporosis (long-term)
+10%
Infections
+7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Prednisone in Inflammatory bowel disease
Fecal Microbiota Transplantation for Ulcerative Colitis
NCT03804931RECRUITINGPHASE2, PHASE3
120 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 20, 2019
Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease
NCT06986382NOT YET RECRUITINGPHASE1, PHASE2
14 participants
INTERVENTIONAL
Palo Alto, United States
Started: Jul 1, 2025
Completed Clinical Trials
9 completed trials for Prednisone in Inflammatory bowel disease
Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease
NCT01981889COMPLETEDPHASE4
53 participants
INTERVENTIONAL
Vancouver, Canada
Started: Oct 1, 2013
Effects of Exclusive Enteral Nutrition on the Microbiome in Pediatric Inflammatory Bowel Disease
NCT02521064COMPLETED
31 participants
OBSERVATIONAL
Hamilton, Canada
Started: Jul 1, 2015
Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD)
NCT06637683COMPLETEDNA
60 participants
INTERVENTIONAL
Thái Bình, Vietnam
Started: Nov 15, 2019
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
NCT01235689COMPLETEDPHASE3
252 participants
INTERVENTIONAL
Started: Feb 11, 2011
Trial of Growth Hormone Therapy in Pediatric Crohn's Disease
NCT00109473COMPLETEDPHASE2
22 participants
INTERVENTIONAL
Cincinnati, United States
Started: Apr 1, 2005
Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster
NCT03553472COMPLETED
97 participants
OBSERVATIONAL
Madison, United States
Started: Jan 1, 2018
Predicting Response to Standardized Pediatric Colitis Therapy
NCT01536535COMPLETEDPHASE4
431 participants
INTERVENTIONAL
Los Angeles, United States +28 more
Started: Jul 10, 2012
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
NCT02619552COMPLETED
50 participants
OBSERVATIONAL
Baltimore, United States +3 more
Started: Aug 1, 2011
Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls
NCT01860963COMPLETEDNA
310 participants
INTERVENTIONAL
Stanford, United States
Started: Jan 1, 2010
Showing 20 of 26 total trials